Oxygen therapy for pulmonary arterial hypertension : we need to rethink and investigate

Simon Green, Deidre Stuart

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is characterized by progressive increases in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR), resulting in right ventricular failure and death. Primary treatment of PAH (Class 1) is based on the use of four classes of drugs in the form of monotherapy or combination therapy. Despite significant advances in drug‐based treatment of PAH and improvements in survival rates, the prognosis for PAH patients remains poor. PAH drugs target mechanisms involved in vasodilation of pulmonary arterial vessels (Fig. 1A), but their vascular effects are not limited to the pulmonary circulation, probably contributing to side effects and limiting drug efficacy. Thus, there is a need for additional therapeutic approaches.
Original languageEnglish
Pages (from-to)470-471
Number of pages2
JournalRespirology
Volume25
Issue number5
DOIs
Publication statusPublished - 2020

Keywords

  • oxygen therapy
  • pulmonary hypertension

Fingerprint

Dive into the research topics of 'Oxygen therapy for pulmonary arterial hypertension : we need to rethink and investigate'. Together they form a unique fingerprint.

Cite this